- Benzinga•3 hours ago
Credit Suisse is bullish on Eli Lilly and Co (NYSE: LLY ), saying the recent FDA delay on rheumatoid arthritis drug baricitinib is only a short-term setback for the pharma major . But, the brokerage acknowledges ...
- Investopedia•8 hours ago
Biotech stocks had a rough year in 2016, overall. The new year has brought new optimism among some investors, but there are still reasons to be cautious.
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).
INCY : Summary for Incyte Corporation - Yahoo Finance
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||113.91 x 100|
|Ask||113.99 x 200|
|Day's Range||113.24 - 116.13|
|52 Week Range||55.00 - 121.18|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||309.17|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|